Brain tissue homogenates and serum samples were collected to quantify intestinal permeability markers (zonulin and occluding), oxidative-stress markers (GSH, MDA, CAT), and GABA-receptor gene expression using ELISA and biochemical assays
Case 2: Due to a national shortage of 1.0 mg semaglutide, a female whose weight was previously stable on phentermine 15mg/topiramate 25mg twice daily plus GLP-1 agonist therapy (i.e., semaglutide) was switched to 5mg tirzepatide in-between clinic visits
From there, you can continue the once weekly dosing schedule
Real evidence: A 12-week study: submaximal semaglutide improved metabolic markers but showed no change in the inflammatory markers IL-6, TNF-, or PAI-1 Semaglutide dose-response studies: effects require 0.2 mg/day, and even those effects are diminished when adjusted for weight change Meta-analyses showing anti-inflammatory effects correlate with improvements in insulin resistance and weight loss, not with microdosing voodoo magic
Another factor to remember while on GLP1 therapy is that it is important to include strength training/muscle strengthening, and sufficient protein in the diet, so as to reduce muscle loss
